Ubs Asset Management Americas Inc Ocugen, Inc. Transaction History

Ubs Asset Management Americas Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$1.11 - $1.87 $172,821 - $291,149	-155,695 Reduced 49.74%	157,292 $204,000
Q2 2022 Aug 12, 2022	BUY	$1.83 - $3.45 $173,031 - $326,207	94,553 Added 43.29%	312,987 $710,000
Q1 2022 May 16, 2022	BUY	$2.34 - $4.72 $43,034 - $86,805	18,391 Added 9.19%	218,434 $720,000
Q4 2021 Feb 14, 2022	BUY	$4.38 - $15.67 $60,829 - $217,624	13,888 Added 7.46%	200,043 $910,000
Q3 2021 Nov 15, 2021	BUY	$6.36 - $8.51 $58,085 - $77,721	9,133 Added 5.16%	186,155 $1.34 Million
Q2 2021 Aug 16, 2021	BUY	$5.52 - $15.68 $977,161 - $2.78 Million	177,022 New	177,022 $1.42 Million

125

78.3M

535K

523K

Ticker OCGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,566,000
Market Cap $197M
Description
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmento...

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

Stay updated on Ubs Asset Management Americas Inc with notifications on news.